Research Synthesis: Melatonin aging — full paper

Researka accepted publication: 5e2a61ca-d8e8-4213-a48c-4774ee35a459 Source submission: 7ec26cef-373b-47c9-8479-9a8c0bf42304 This paper synthesizes evidence on Melatonin aging across 50 accepted source papers and 2895 high-confidence extracted claims. The evidence profile contains 17 direct clinical sources, 33 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 581 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the cardiometabolic and longevity outcome classes, null signals in the contextual adjacent evidence, dosing and pharmacokinetics, safety and comorbidity outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that Melatonin aging remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.